MONCTON, NEW BRUNSWICK--(Marketwired - June 1, 2017) - Organigram Holdings Inc. - (TSX VENTURE:OGI)(OTCQB:OGRMF) ("Organigram" or the "Company") is pleased to announce the finalized acquisition of Trauma Healing Centers Incorporated ("THC") with a final transaction date of June 1, 2017.

"We are excited to complete the formal acquisition process and look forward to continuing our working relationship with THC and their staff" said Greg Engel, CEO of Organigram. "Over the past two years, both companies have worked very well together and we're excited to further our work in supporting medical cannabis patients across Canada".

Trauma Healing Centers currently services over 3,500 patients across seven Canadian locations with plans to open seven more locations. "The relationship with Organigram will allow us the resources and expertise to increase our footprint and offer support to more potential patients across Canada" said Kyle Atkinson, President of Trauma Healing Centers. "Our strategic vision for Trauma Healing Centers is very much based on aggressive expansion, and we feel Organigram is the perfect partner to help us achieve this goal."

As previously communicated, THC will join the Organigram group thereby consolidating two leading medicinal cannabis players within the industry. THC will continue to operate independently by providing referrals based on client need to any licensed producer in Canada.

The finalized agreement consists of the issuance of 719,425 common shares of Organigram at a deemed value of $2.78 per share.

For more information about Trauma Healing Centers visit

For more information visit

About Organigram Holdings Inc.

Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram's facility is located in Moncton, New Brunswick and the Company is regulated by the Access to Cannabis for Medical Purposes Regulations ("ACMPR").

In February 2017, Organigram was ranked in the top ten Clean Technology & Life Sciences Sector on the TSX Venture Exchange 50.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, crop yields - that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:

Organigram Holdings Inc.
Greg Engel
Chief Executive Officer

Organigram Holdings Inc.
Giselle Doiron
Director of Investor and Media Relations
(506) 801-8986